Instrument Inactif

Communiqués Bionomics OTC Markets

Actions

08/12	Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director Nominees	AQ
04/12	Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium	AQ
01/12	Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions	AQ
24/11	Neuphoria Therapeutics Inc. Sends Letter to Stockholders	AQ
11/11	Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value	AQ
27/10/25	Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process	AQ
20/10/25	Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder	AQ
29/09/25	Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates	AQ
04/09/25	Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)	AQ
28/08/25	Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference	AQ
27/05/25	Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting	AQ
20/05/25	Neuphoria Provides First Quarter 2025 Business Updates	AQ
15/04/25	Neuphoria Provides a Review of 2024 and Highlights 2025 Plans	AQ
03/03/25	Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025	AQ
12/02/25	Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck	AQ